UP Strategic Wealth Investment Advisors LLC Purchases 29 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

UP Strategic Wealth Investment Advisors LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 452 shares of the medical research company’s stock after acquiring an additional 29 shares during the period. UP Strategic Wealth Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $250,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Brookstone Capital Management grew its position in Thermo Fisher Scientific by 252.4% in the 1st quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock valued at $2,550,000 after acquiring an additional 3,142 shares during the last quarter. Artisan Partners Limited Partnership purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $40,335,000. Leo Wealth LLC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $1,117,000. Rhenman & Partners Asset Management AB raised its position in Thermo Fisher Scientific by 6,600.0% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 33,500 shares of the medical research company’s stock valued at $17,781,000 after purchasing an additional 33,000 shares in the last quarter. Finally, BDF Gestion bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $6,368,000. Institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on TMO. Jefferies Financial Group reaffirmed a “buy” rating and issued a $650.00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Wells Fargo & Company initiated coverage on Thermo Fisher Scientific in a report on Tuesday, August 27th. They issued an “overweight” rating and a $670.00 price target on the stock. UBS Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research note on Monday. Stifel Nicolaus boosted their price objective on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Finally, Barclays reduced their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $632.89.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $610.12 on Thursday. The stock has a market capitalization of $233.07 billion, a PE ratio of 39.14, a price-to-earnings-growth ratio of 2.86 and a beta of 0.78. The stock’s 50-day moving average price is $596.69 and its 200-day moving average price is $580.98. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. The firm had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter last year, the company earned $5.15 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be given a $0.39 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 860 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $611.03, for a total transaction of $525,485.80. Following the transaction, the chief accounting officer now directly owns 1,814 shares in the company, valued at $1,108,408.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, VP Lisa P. Britt sold 3,624 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the transaction, the vice president now directly owns 13,699 shares in the company, valued at approximately $8,397,760.98. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Joseph R. Holmes sold 860 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $611.03, for a total transaction of $525,485.80. Following the completion of the sale, the chief accounting officer now owns 1,814 shares in the company, valued at $1,108,408.42. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,084 shares of company stock worth $14,094,292. Corporate insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.